KK
BBIO icon

KLP Kapitalforvaltning’s BridgeBio Pharma BBIO Stock Holding History

KLP Kapitalforvaltning’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.48M Buy
33,235
+1,300
+4% +$91.1K 0.01% 677
2026
Q1 		$2.37M Hold
31,935
– – 0.01% 648
2025
Q4 		$2.44M Buy
31,935
+2,200
+7% +$144K 0.01% 640
2025
Q3 		$1.54M Buy
29,735
+1,700
+6% +$82.9K 0.01% 799
2025
Q2 		$1.21M Buy
28,035
+4,700
+20% +$171K 0.01% 879
2025
Q1 		$807K Sell
23,335
-1,900
-8% -$64.1K ﹤0.01% 1045
2024
Q4 		$692K Buy
+25,235
New +$652K ﹤0.01% 1172

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

KLP Kapitalforvaltning's BBIO Position: Q2 2026 in Review

KLP Kapitalforvaltning increased its BridgeBio Pharma (BBIO) stake by 4.1% in Q2 2026, buying an estimated $91.1K and bringing the position to 33,235 shares worth $2.48M. The position accounts for 0.01% of the portfolio, ranked #677.

KLP Kapitalforvaltning first reported a position in BBIO in Q4 2024 and has held it in 7 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • KLP Kapitalforvaltning held 33,235 shares of BridgeBio Pharma worth $2.48M as of Q2 2026.
  • KLP Kapitalforvaltning bought 1,300 BridgeBio Pharma shares in Q2 2026, an estimated $91.1K.
  • BridgeBio Pharma made up 0.01% of KLP Kapitalforvaltning's portfolio in Q2 2026, its #677 holding.
  • KLP Kapitalforvaltning first reported a position in BridgeBio Pharma in Q4 2024 and has held it in 7 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on KLP Kapitalforvaltning's 13F filing for Q2 2026, filed 12 Aug 2026.